Table 1.

The reduction of COVID-19 comorbidity risk by TPs.

Comorbidity	Risk	Experimental model	Results	Reference
Pulmonary fibrosis	33%	EGCG doses of 300–400 mg/kg	>99% reduction in interstitial and peribronchial fibrosis and ~50% reduction in perivascular fibrosis	(74)
Diabetes	17%	Drink ≥ 6 cups a day	33% lower risk of diabetes	(83)
Depression	25%	Drink ≥ 4 cups a day	51% lower prevalence of depressive symptoms	(88)